RECOVERY Collaborative Group2021-06-042021-06-042021-05-07RECOVERY Collaborative Group 2021, 'Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial', The Lancet, vol. 397, no. 10285, pp. 1637-1645. https://doi.org/10.1016/S0140-6736(21)00676-00140-6736Bibtex: 20211637PubMedCentral: PMC8084355ORCID: /0000-0002-1397-4272/work/95222694ORCID: /0000-0003-2115-8184/work/117057617ORCID: /0000-0003-3812-7026/work/188766568https://hdl.handle.net/2164/16630Acknowledgments Above all, we thank the thousands of patients who participated in this study. We also thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at 176 NHS hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health & Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage at the University of Swansea, and the NHS in England, Scotland, Wales, and Northern Ireland. The RECOVERY trial is supported by a grant to the University of Oxford from UK Research and Innovation–NIHR (Grant reference: MC_PC_19056) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill & Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC_UU_0002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. AbbVie contributed some supplies of lopinavir–ritonavir for use in this study. Roche Products supported the trial through the provision of tocilizumab. REGEN-COV2 was provided for this study by Regeneron. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, or Roche Products. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research. The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the appendix (pp 2–25)9935768engAdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, Humanized/administration & dosageCOVID-19/complicationsFemaleHospital MortalityHospitalizationHumansHypoxia/diagnosisMaleMiddle AgedOxygen SaturationRespiration, Artificial/statistics & numerical dataSARS-CoV-2/isolation & purificationSeverity of Illness IndexTreatment OutcomeYoung AdultCOVID-19 Drug TreatmentR MedicineMedical Research Council (MRC)National Institute for Health Research (NIHR)RJournal article10.1016/S0140-6736(21)00676-039710285